Los Angeles Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Los Angeles Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,970	Closed	-$87.8K	–	2331
2026 Q1	$87.8K	Hold	35,970	–	–	﹤0.01%	1364
2025 Q4	$43.5K	Hold	35,970	–	–	﹤0.01%	1648
2025 Q3	$44.6K	Hold	35,970	–	–	﹤0.01%	1340
2025 Q2	$40.6K	Buy	+35,970	New	+$47.8K	﹤0.01%	1318
2024 Q3	–	Sell	-125,030	Closed	-$291K	–	1158
2024 Q2	$291K	Sell	125,030 -35,593	-22%	-$105K	﹤0.01%	1021
2024 Q1	$718K	Sell	160,623 -5,355	-3%	-$22.3K	﹤0.01%	782
2023 Q4	$533K	Buy	+165,978	New	+$471K	﹤0.01%	851
2023 Q3	–	Sell	-41,227	Closed	-$205K	–	1110
2023 Q2	$205K	Buy	+41,227	New	+$223K	﹤0.01%	1116
2021 Q4	–	Sell	-25,283	Closed	-$650K	–	1384
2021 Q3	$650K	Sell	25,283 -5,230	-17%	-$124K	﹤0.01%	938
2021 Q2	$796K	Sell	30,513 -3,087	-9%	-$88K	﹤0.01%	953
2021 Q1	$1.19M	Sell	33,600 -10,635	-24%	-$359K	0.01%	814
2020 Q4	$1.12M	Sell	44,235 -900	-2%	-$29.3K	﹤0.01%	890
2020 Q3	$1.7M	Sell	45,135 -3,420	-7%	-$129K	0.01%	611
2020 Q2	$2.08M	Buy	+48,555	New	+$1.76M	0.01%	603

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Los Angeles Capital Management's ALLO Position: Q2 2026 in Review

Los Angeles Capital Management sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 35,970 shares — an estimated $87.8K sold.

Los Angeles Capital Management first reported a position in ALLO in Q2 2020 and held it in 14 quarters. The position peaked at $2.08M in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Los Angeles Capital Management reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
Los Angeles Capital Management sold 35,970 Allogene Therapeutics shares in Q2 2026, an estimated $87.8K.
Los Angeles Capital Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 14 quarters.
Los Angeles Capital Management's Allogene Therapeutics position peaked at $2.08M in Q2 2020.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.